Even in the era of ART (Antiretroviral Therapy), HIV Associated Neurocognitive Disorder (HAND) is still prevalent. It may have been associated in some way with CD4 counts, disease duration, and the duration of treatments. This cross-sectional study was conducted at a tertiary care hospital in Raipur, Chhattisgarh, India. To determine the association of HIV-associated neurocognitive disorder with mini-mental state examination score (MMSES) and its correlation with CD4 counts, disease duration, and art regimen. Patients who meet the inclusion criteria are seen at the ART Centre, in the clinical OPD outpatient department, or hospitalized in the medical ward throughout the year from November 2021 to October 2022. People living with HIV(PLWH) underwent screening-validated methods to diagnose HIV-associated neurocognitive disorders (HAND) in central India. This study includes 92 HIV patients in total. The mean age of study subjects was 37.5 ± 12.76 years. 60.87% were male, and 39.13% were female study subjects. The mean mental score and CD4 counts among the study subjects were 23.29 ± 0.30 with [CI: 22.68-23.90] and 346.04 ± 22.29 with [301.75-390.33], respectively, and the prevalence of HAND was 52.17%. Between HAND, CD4 counts, and HIV disease duration, a significant correlation was found. This study concludes that the MMSES is a test for detecting HIV-associated neurocognitive disorder and the correlation between HAND and CD4 counts and HIV disease duration. Disease. However, the correlation between HAND and the duration of the ART regimen was insignificant.
UNAIDS data 2019; 2019 [cited Dec 04, 2019]. Available from: https://www.unaids.org/sites/default/files/media European Review for Medical and Pharmacological Sciences_asset/2019-UNAIDS-data_en.pdf.
Global statistics; 2016. Aids.gov [cited Nov 28, 2016]. Available from. Available from: http://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics.
UNAIDS/UNAIDS/JC2656 (English original, July 2014, updated September 2014) ISBN 978-92-9253-062-4.The Gap report; 2014. p. 58.
NACO, Ministry of Health and Family Welfare, Government of India. India HIV estimations 2015 technical report. New Delhi; 2016. p. 3.
Harrison MJG, MJ. AIDS and neurology. Edinburgh: Churchill Livingstone; 1995.
Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (Lond Engl). 2010;24(9):1243-50. doi: 10.1097/QAD.0b013e3283354a7b, PMID 19996937.
McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: Is there a hidden epidemic? AIDS (Lond Engl). 2010;24(9):1367-70). doi: 10.1097/QAD.0b013e3283391d56, PMID 20559041.
Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: The longitudinal CHARTER study. Clin Infect Dis. 2015;60(3):473-80). doi: 10.1093/cid/ciu862, PMID 25362201.
Lamarre CJ, Patten SB. Can J Psychiatry. Evaluation of the Modified Mini-Mental State Examination in a general psychiatric population. 1991;36(7):507-11. doi: 10.1177/070674379103600708, PMID 1933759.
Folstein MF, Folstein SE, McHugh PR. ’Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6, PMID 1202204.
Galea M, Woodward M. Mini-Mental State Examination (MMSE). Aust J Physiother. 2005 Jan 1;51(3):198. doi: 10.1016/s0004-9514(05)70034-9, PMID 16187459.
Faber RA. The neuropsychiatric mental status examination. Semin Neurol. 2009;29(3):185-93. Level of evidence C. doi: 10.1055/s-0029-1223874, PMID 19551596.
Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria. BMJ, (Open). 2012 Feb 13;2(1):e000662. doi: 10.1136/bmjopen-2011-000662, PMID 22331389.
Oshinaike OO, Akinbami AA, Ojo OO, Ojini IF, Okubadejo UN, Danesi AM. Comparison of the Minimental State examination scale and the International HIV dementia scale in assessing cognitive function in Nigerian HIV patients on antiretroviral therapy. AIDS Res Treat. 2012;2012:581531. doi: 10.1155/2012/581531, PMID 23050130.
Achappa B, Priyadarshni S, Madi D, Bhaskaran U, Ramapuram JT, Rao S et al. Neurocognitive dysfunction among HIV positive patients using International HIV dementia scale. Asian J Med Sci. 2014;5(4):61-4. doi: 10.3126/ajms.v5i4.8724.
Kelly CM, van Oosterhout JJ, Ngwalo C, Stewart RC, Benjamin L, Robertson KR et al. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross-sectional study. PLOS ONE. 2014 Jun 10;9(6):e98962. doi: 10.1371/journal.pone.0098962, PMID 24915530.
Balaini N, Sharma A, Sharma S, Sharma A. HIV associated neurocognitive dysfunction and its association with CD4 count in HIV positive patients-a hospital-based study. Intl JRes Med Sci. 2017;5:4259-66.
Mohamed AA, Oduor C, Kinyanjui D. HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya. BMC Neurol. 2020;20(1):280. doi: 10.1186/s12883-020-01857-3, PMID 32664858.
Kumar S, Himanshu D, Tandon R, Atam V, Sawlani KK, Verma SK. Prevalence of HIV-associated neurocognitive disorder using modified mini-mental state examination and its correlation with CD4 counts and anti-retroviral therapy. J Assoc Physicians India. 2019 Apr;67(4):47-51. PMID 31299839.
Holyachi MShakilA et al. Neurological manifestation with special reference to HIV-associated neurocognitive disorder (HAND) among people on anti-retroviral treatment in India. R A Shaik, S. Eur Rev Med Pharmacol Sci. Nov 2021.
Salahuddin M, Manzar MD, Hassen HY, Unissa A, Abdul Hameed U, Spence DW et al. Prevalence and predictors of neurocognitive impairment in Ethiopian population living with HIV. HIV Aids (Auckl). 2020 Oct 13;12:559-72. doi: 10.2147/HIV.S260831, PMID 33116918, PMCID PMC7568595.
